PMID- 37251681
OWN - NLM
STAT- MEDLINE
DCOM- 20230601
LR  - 20230602
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 14
DP  - 2023
TI  - Abiraterone acetate and prednisone in metastatic castration-resistant prostate 
      cancer: a real-world retrospective study in China.
PG  - 1158949
LID - 10.3389/fendo.2023.1158949 [doi]
LID - 1158949
AB  - BACKGROUND: This research work was aimed at evaluating the incidence and risk 
      factors of adverse events (AEs) occurring in patients treated with abiraterone 
      acetate (AA) and prednisone (PDN) outside clinical trials. These associations 
      were assessed regarding the survival outcomes. METHODS: The study included 191 
      patients aged >/=18 years of confirmed metastatic castration-resistant prostate 
      cancer (mCRPC) between March 2017 and April 2022. AE incidences were 
      descriptively summarized from the whole cohort. Baseline characteristics, safety 
      (treatment-emergent AEs and severe AEs), and efficacy [progression-free survival 
      (PFS)] were analyzed. Multi-variable Cox proportional hazards models were 
      employed to assess the factors linked with PFS. RESULTS: Overall, the median PFS 
      was 17.16 months (range, 0.5-57.58). Patient baseline prostate-specific antigen 
      (PSA) >=≠10 ng/ml (p = 0.000), multiple organ metastasis (p = 0.007), hypertension 
      (p = 0.004), and coronary heart disease (p = 0.004) were associated with worse 
      PFS; however, radiotherapy (p = 0.028) was linked to better PFS at univariate 
      analysis in the overall cohort. Baseline multiple organ metastasis, hypertension, 
      and radiotherapy remained statistically significant in multivariable models (p = 
      0.007, p= 0.005, and p = 0.011, respectively).Incidence of AEs showed increased 
      bilirubin (BIL) (55/191 patients, 28.8%) followed by increased alanine 
      aminotransferase/aspartate aminotransferase (ALT/AST) (48/191 patients, 25.09%). 
      The most common grade 3 AEs were increased ALT (3/191, 1.57%) followed by 
      elevated BIL, hypercholesterolemia, and hypokalemia. Anemia had shorter PFS. 
      There were no unexpected AEs in any patient. CONCLUSION: AA is effective and 
      tolerated in asymptomatic or slightly symptomatic mCRPC in "real-life" setting. 
      The survival outcomes are influenced by multiple organ metastasis, hypertension, 
      and radiotherapy.
CI  - Copyright (c) 2023 Liu, Yan, Le, Li, Xing and Li.
FAU - Liu, Min
AU  - Liu M
AD  - Department of Pharmacy, National Cancer Center/National Clinical Research Center 
      for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union 
      Medical College, Beijing, China.
FAU - Yan, Jiaqing
AU  - Yan J
AD  - Department of Pharmacy, National Cancer Center/National Clinical Research Center 
      for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union 
      Medical College, Beijing, China.
FAU - Le, Kaidi
AU  - Le K
AD  - Department of Pharmacy, National Cancer Center/National Clinical Research Center 
      for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union 
      Medical College, Beijing, China.
FAU - Li, Ying
AU  - Li Y
AD  - Department of Pharmacy, National Cancer Center/National Clinical Research Center 
      for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union 
      Medical College, Beijing, China.
FAU - Xing, Nianzeng
AU  - Xing N
AD  - Department of Urology, National Cancer Center/National Clinical Research Center 
      for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union 
      Medical College, Beijing, China.
FAU - Li, Guohui
AU  - Li G
AD  - Department of Pharmacy, National Cancer Center/National Clinical Research Center 
      for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union 
      Medical College, Beijing, China.
LA  - eng
PT  - Journal Article
DEP - 20230512
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
RN  - EM5OCB9YJ6 (Abiraterone Acetate)
RN  - VB0R961HZT (Prednisone)
SB  - IM
MH  - Male
MH  - Humans
MH  - Adolescent
MH  - Adult
MH  - Abiraterone Acetate/adverse effects
MH  - Prednisone/adverse effects
MH  - *Prostatic Neoplasms, Castration-Resistant/drug therapy/pathology
MH  - Retrospective Studies
MH  - *Hypertension/drug therapy
PMC - PMC10213513
OTO - NOTNLM
OT  - PSA
OT  - abiraterone
OT  - castration-resistant prostate cancer
OT  - outcome
OT  - progression
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/05/30 13:07
MHDA- 2023/06/01 06:42
PMCR- 2023/01/01
CRDT- 2023/05/30 11:42
PHST- 2023/02/04 00:00 [received]
PHST- 2023/04/21 00:00 [accepted]
PHST- 2023/06/01 06:42 [medline]
PHST- 2023/05/30 13:07 [pubmed]
PHST- 2023/05/30 11:42 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fendo.2023.1158949 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2023 May 12;14:1158949. doi: 
      10.3389/fendo.2023.1158949. eCollection 2023.